Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

This study found that using GLP-1 RAs and SGLT2is for type 2 diabetes treatment offers potential neuroprotections against Alzheimer disease and related dementias. HealthDay News — Both glucagon ...

Just days after Pfizer pulled its experimental obesity pill, Eli Lilly announced promising results for its oral GLP-1. The pharma giant announced Thursday morning that its oral GLP-1 drug advanced ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...